Epidemiology of extended-spectrum β-lactamase, AmpC, and carbapenemase production in Proteus mirabilis

Japanese Journal of Infectious Diseases

Volumn 67, Issue 1, 2014, Pages 44-46

  Datta, Priya ^a   Gupta, Varsha ^a   Arora, Shilpa ^a   Garg, Shivani ^a   Chander, Jagdish ^a  

^a GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

AmpC; Carbapenemase; ESBL; Proteus mirabilis

Indexed keywords

BETA-LACTAMASES; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; PREVALENCE; PROTEUS INFECTIONS; PROTEUS MIRABILIS;

EID: 84892765572     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.67.44     Document Type: Article

References (16)

1. Pagani, L., Migliavacca, R., Pallecchi, L., et al. (2002): Emerging extended-spectrum b-lactamases in Proteus mirabilis. J. Clin. Microbiol., 40, 1549-1552.
2. Tenover, F.C., Emery, S.L., Spiegel, C.A., et al. (2009): Identification of plasmid-mediated Amp-C b-lactamases in Escherichia coli, Klebsiella spp., and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J. Clin. Microbiol., 47, 294-299.
3. Tibbetts, R., Frye, J.G., Marschall, J., et al. (2008): Detection of KPC-2 in a clinical isolate of Proteus mirabilis and first reported description of carbapenemase resistance caused by a KPC b-lactamases in Proteus mirabilis. J. Clin. Microbiol., 46, 3080-3083.
4. Clinical and Laboratory Standards Institute (CLSI) (2011): Performance standards for antimicrobial susceptibility testing: 21st informational supplement M100-S21. CLSI, Wayne, Pa, USA.
5. Kenneth, S.T. (2010): Extended-spectrum b-lactamases, AmpC, and carbapenemase issues. J. Clin. Microbiol., 48, 1019-1025.
6. Gary, D.O. (2010): Carbapenemases. A brief review for pediatric infectious disease specialists. Pediatr. Infect. Dis. J., 29, 68-70.
7. Collee, J.G., Miles, R.S. and Watt, B. (1996): Tests for the identification of bacteria. p. 151-179. In Collee, J.G., Fraser, A.G., Marmion, B.P., et al. (eds), Mackie & MacCartney Practical Medical Microbiology. 14th ed. Churchill Livingstone, London.
8. Black, J.A., Moland, E.S. and Thomson, K.S. (2005): AmpC disk test for detection of plasmid-mediated AmpC b-lactamases in Enterobacteriaceae lacking chromosomal AmpC b-lactamases. J. Clin. Microbiol., 43, 3110-3113.
9. Jacoby, G.A. (2009): AmpC b-lactamases. Clin. Microbiol. Rev., 22, 161-182.
10. Rudresh, S.M. and Nagarathnamma, T. (2011): Extended spectrum b-lactamase producing Enterobacteriaceae & antibiotic coresistance. Indian J. Med. Res., 133, 116-118.
11. Khan, M.K.R., Thukral, S.S. and Gaind, R. (2008): Evaluation of a modified double-disc synergy test for detection of extended spectrum b-lactamases in Amp C b-lactamase-producing Proteus mirabilis. Indian J. Med. Microbiol., 26, 58-61.
12. Thomson, K.S. (2001): Controversies about extended-spectrum and AmpC beta-lactamases. Emerg. Infect. Dis., 7, 333-336.
13. Munier, G.K., Johnson, C.L., Snyder, J.W., et al. (2010): Positive extended-spectrum-b-lactamase (ESBL) screening results may be due to AmpC-lactamases more often than to ESBLs. J. Clin. Microbiol., 48, 673-674.
14. Gupta, E., Mohanty, S., Sood, S., et al. (2006): Emerging resistance to carbapenem in a tertiary care hospital in North India. Indian J. Med. Res., 124, 95-98.
15. Prakash, S. (2006): Carbapenem sensitivity profile amongst bacterial isolates from clinical specimens in Kanpur city. Indian J. Crit. Care Med., 10, 250-253.
16. Gupta, N., Limbago, B.M., Patel, J.B., et al. (2011): Carbapenem-resistant Enterobacteriaceae; epidemiology and prevention. Clin. Infect. Dis., 53, 60-67.